VRCA Stock Analysis: Buy, Sell, or Hold?
VRCA - Verrica Pharmaceuticals Inc. Common Stock
$4.76
0.38 (8.68%)
▲
5d:
-1.86%
30d:
-12.98%
90d:
-41.67%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 12, 2026
Get Alerted When VRCA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VRCA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: VRCA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: VRCA is currently trading at $4.76, which is considered oversold relative to its 30-day fair value range of $4.90 to $6.05.
Technical Outlook: Technically, VRCA is showing sideways momentum. Immediate support is located at $4.25, while resistance sits at $6.53. The stock is showing strong short-term momentum, up 8.7% recently.
Market Sentiment: VRCA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $16.50 (+276.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VRCA is showing sideways momentum. Immediate support is located at $4.25, while resistance sits at $6.53. The stock is showing strong short-term momentum, up 8.7% recently.
Market Sentiment: VRCA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $16.50 (+276.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.90 -
$6.05
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.7%)
- BULLISH: Trading 276.7% below Wall St target ($16.50)
Fair Price Analysis
30-Day Fair Range
$4.90 -
$6.05
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$4.25
Resistance Level
$6.53
Current Trend
Sideways
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.57
Wall Street Target
$16.50
(+276.7%)
Revenue Growth (YoY)
1380.2%
Profit Margin
-50.3%
Share & Embed Analysis
Last updated: March 30, 2026 1:58 PM ET
Data refreshes hourly during market hours. Next update: 2:58 PM
Data refreshes hourly during market hours. Next update: 2:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRCA showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David Zawitz
BUY
10000 shares
2025-11-25
Jayson Rieger
BUY
94311 shares
2025-11-25
John J Kirby
BUY
3536 shares
2025-11-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 45 HOLD |
